Recombinant snake antivenoms get closer to the clinic.

Laustsen, Andreas H

Laustsen, Andreas H.

Afiliación

Laustsen AH; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, DK-2800, Denmark. Electronic address: ahola@bio.dtu.dk.

Trends Immunol ; 45(4): 225-227, 2024 Apr.

Article en En | MEDLINE | ID: mdl-38538486

ABSTRACT

ABSTRACT

Snakebite envenomings kill ~100 000 victims each year and leave many more with permanent sequelae. Antivenoms have been available for more than 125 years but are in need of innovation. A new study by Khalek et al. highlights broadly neutralizing human monoclonal antibodies (mAbs) that might be used to develop recombinant antivenoms with superior therapeutic benefits.

Asunto(s)

Antivenenos; Mordeduras de Serpientes; Humanos; Animales; Antivenenos/uso terapéutico; Mordeduras de Serpientes/tratamiento farmacológico; Anticuerpos Monoclonales/uso terapéutico; Serpientes

Palabras clave

Snakebite envenoming; antivenom; broadly-neutralizing antibodies; monoclonal antibodies; recombinant antivenom; snake venom toxins

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Mordeduras de Serpientes / Antivenenos Límite: Animals / Humans Idioma: En Revista: Trends Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google